CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 110 enrolled
Drug / intervention
Trastuzumab emtansine [Kadcyla]drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00679211
NCT00679211Phase 2Completed
CompareCT.gov

A Phase II, Single-Arm, Open-Label Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

Genentech, Inc.·interventional·Posted May 16, 2008·Updated Mar 31, 2017

In Brief

A Phase 2 clinical trial evaluating Trastuzumab emtansine [Kadcyla] for Metastatic Breast Cancer. Completed, enrolled 110 participants.

Detailed Summary

Study of trastuzumab emtansine (T-DM1) administered to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 16, 2008
Enrollment StartAug 1, 2008
Primary CompletionSep 1, 2009
Study CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.1 years ago

Interventions

Trastuzumab emtansine [Kadcyla]drug

Intravenous repeating dose